Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Antiplatelet

Therapeutic area intelligence for Antiplatelet with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 7
Catalysts: 0
Companies: 4

Companies

AstraZeneca →

cardiovascular therapeutics →

Assets

Dipyidamole →

Recent signals(7)

RegulatoryAugust 11, 2026

FDA grants AP status for ANDA207944 containing Aspirin and Dipyridamole

The FDA has granted approval status (AP) for ANDA207944, a supplemental application by PH Health for a product containing Aspirin and Dipyridamole.

RegulatoryAugust 5, 2026

FDA Accepts Supplemental NDA for Brilinta (Ticagrelor) by AstraZeneca

The FDA has accepted a supplemental NDA for Brilinta (ticagrelor) submitted by AstraZeneca.

RegulatoryJuly 30, 2026

FDA Approves Ticagrelor Application ANDA208539 by Micro Labs

The FDA has approved the original application for Ticagrelor (ANDA208539) submitted by Micro Labs.

ClinicalJuly 30, 2026

Study Compares IV vs Oral Aspirin in Healthy Adults

A clinical trial is underway to evaluate the pharmacokinetics, pharmacodynamics, and safety of intravenous versus oral aspirin.

RegulatoryJuly 25, 2026

FDA Approves Cangrelor for Market Release

The FDA has granted approval for Cangrelor under application ANDA213703, submitted by MSN.

RegulatoryJuly 13, 2026

FDA Approves Supplemental Application for BRILINTA (Ticagrelor)

The FDA has approved a supplemental application for BRILINTA, a medication containing ticagrelor, submitted by AstraZeneca.

RegulatoryJune 30, 2026

Hikma's Dipyidamole ANDA074521 Receives AP Status from FDA

Hikma's ANDA074521 for Dipyidamole has received an Abbreviated Approval (AP) status from the FDA.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.